ZA200904907B - Antibodies against human cytomegalovirus (hCMV) - Google Patents

Antibodies against human cytomegalovirus (hCMV)

Info

Publication number
ZA200904907B
ZA200904907B ZA200904907A ZA200904907A ZA200904907B ZA 200904907 B ZA200904907 B ZA 200904907B ZA 200904907 A ZA200904907 A ZA 200904907A ZA 200904907 A ZA200904907 A ZA 200904907A ZA 200904907 B ZA200904907 B ZA 200904907B
Authority
ZA
South Africa
Prior art keywords
methods
human
cells
secrete
human cytomegalovirus
Prior art date
Application number
ZA200904907A
Other languages
English (en)
Inventor
Ada Funaro
Giorgio Gribaudo
Santo Landolfo
Original Assignee
Ribovax Biotechnologies Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribovax Biotechnologies Sa filed Critical Ribovax Biotechnologies Sa
Publication of ZA200904907B publication Critical patent/ZA200904907B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
ZA200904907A 2005-12-16 2009-07-14 Antibodies against human cytomegalovirus (hCMV) ZA200904907B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2005056871 2005-12-16
PCT/EP2006/069780 WO2007068758A1 (en) 2005-12-16 2006-12-15 Methods for obtaining immortalized antibody secreting cells

Publications (1)

Publication Number Publication Date
ZA200904907B true ZA200904907B (en) 2010-04-28

Family

ID=36685876

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200806094A ZA200806094B (en) 2005-12-16 2008-07-14 Methods for obtaining immortalized antibody secreting cells
ZA200904907A ZA200904907B (en) 2005-12-16 2009-07-14 Antibodies against human cytomegalovirus (hCMV)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ZA200806094A ZA200806094B (en) 2005-12-16 2008-07-14 Methods for obtaining immortalized antibody secreting cells

Country Status (20)

Country Link
US (1) US8338172B2 (xx)
EP (1) EP1974020B1 (xx)
JP (2) JP5431730B2 (xx)
KR (1) KR101508945B1 (xx)
CN (1) CN101374944B (xx)
AT (1) ATE513034T1 (xx)
AU (1) AU2006325236B2 (xx)
BR (1) BRPI0619908A2 (xx)
CA (1) CA2633601C (xx)
DK (1) DK1974020T3 (xx)
EA (1) EA019505B1 (xx)
ES (1) ES2367322T3 (xx)
HK (1) HK1127783A1 (xx)
IL (1) IL192095A0 (xx)
NO (1) NO20083160L (xx)
NZ (1) NZ569816A (xx)
PL (1) PL1974020T3 (xx)
PT (1) PT1974020E (xx)
WO (1) WO2007068758A1 (xx)
ZA (2) ZA200806094B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
US8202518B2 (en) 2007-07-04 2012-06-19 Ribovax Biotechnologies S.A. Antibodies against human cytomegalovirus (HCMV)
JP5797403B2 (ja) 2007-08-03 2015-10-21 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント ヒトモノクローナル抗体およびそれを産生する方法
US20110171233A1 (en) * 2007-08-22 2011-07-14 Ribovax Biotechnologies S.A. Antibodies Against Human Cytomegalovirus (HCMV)
NZ707788A (en) 2008-07-16 2016-08-26 Inst Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
US8703486B2 (en) 2008-09-23 2014-04-22 UNIVERSITé LAVAL Method for polyclonal immunoglobulin G production by human B cells
KR101778317B1 (ko) 2009-08-13 2017-09-13 얀센 백신스 앤드 프리벤션 비.브이. 사람 호흡기 세포융합 바이러스(ｒｓｖ)에 대한 항체 및 이용 방법
EP3037435B1 (en) 2009-11-17 2019-08-07 MUSC Foundation for Research Development Human monoclonal antibodies to human nucleolin
EA201270662A1 (ru) 2009-12-23 2013-01-30 4-Антибоди Аг Связывающие элементы для человеческого цитамегаловируса
EP2400298B1 (en) * 2010-05-28 2013-08-14 F.Hoffmann-La Roche Ag Single B-cell cultivation method and specific antibody production
TWI627964B (zh) 2010-07-09 2018-07-01 傑森疫苗防護公司 抗-人類呼吸道融合性病毒（ｒｓｖ）抗體及其使用方法
CN102839152A (zh) * 2011-06-20 2012-12-26 中国科学院上海生命科学研究院 一种快速高效获得抗原特异性b细胞的方法
EP2724157B1 (en) 2011-06-27 2017-03-08 Valneva Method for screening cells
US9757458B2 (en) * 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
DK2797951T3 (en) 2011-12-28 2018-03-12 Immunoqure Ag PROCEDURE FOR ISOLATING HUMAN ANTIBODIES.
WO2014093786A1 (en) * 2012-12-14 2014-06-19 Abbvie, Inc. Methods for increasing the efficiency of hybridoma generation
JP6421944B2 (ja) * 2013-01-03 2018-11-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ サッカロミセス・セレビシエでの発現によって分泌可能な抗体を製造する方法
WO2015001047A1 (en) 2013-07-03 2015-01-08 Immunoqure Ag Method of providing anti-human cytokine antibodies for pharmaceutical use
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3562936A1 (en) * 2017-01-02 2019-11-06 H. Hoffnabb-La Roche Ag B-cell cultivation method
WO2018140733A1 (en) * 2017-01-27 2018-08-02 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN111647566A (zh) * 2019-07-10 2020-09-11 广州医科大学附属第一医院 一种高滴度eb病毒的制备方法、eb病毒永生化记忆性b细胞的方法与应用
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
CN117230258B (zh) * 2023-11-10 2024-04-09 苏州驾玉生物医药有限公司 一种提高灵敏度的培养扩增联合pcr的eb病毒检测方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997764A (en) * 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
JPH05500608A (ja) * 1989-09-19 1993-02-12 セントカー・インコーポレーテツド ヒトモノクローナル抗体の産生を改良する方法
ATE449853T1 (de) 1990-02-01 2009-12-15 Siemens Healthcare Diagnostics HERSTELLUNG UND VERWENDUNG VON GENBANKEN MENSCHLICHER ANTIKÖRPER(ßHUMAN-ANTIKÖRPER- BIBLIOTHEKENß)
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6399384B1 (en) * 1999-09-17 2002-06-04 Reneuron Limited Conditional immortalization of cells
FR2817875B1 (fr) * 2000-12-07 2005-03-18 Technopharm Procede de preparation d'un anticorps monoclonal humain, de fragments de celui-ci ou d'anticorps comprenant de tels fragments, les anticorps ainsi obtenus et leur utilisation
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
GB2398783A (en) * 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
WO2007063415A2 (en) * 2005-08-23 2007-06-07 Iq Corporation Methods of producing stable b-lymphocytes

Also Published As

Publication number Publication date
EA019505B1 (ru) 2014-04-30
JP2013255515A (ja) 2013-12-26
DK1974020T3 (da) 2011-10-03
EP1974020A1 (en) 2008-10-01
AU2006325236A1 (en) 2007-06-21
KR101508945B1 (ko) 2015-04-08
NO20083160L (no) 2008-09-10
PL1974020T3 (pl) 2011-11-30
JP2009519026A (ja) 2009-05-14
HK1127783A1 (en) 2009-10-09
JP5431730B2 (ja) 2014-03-05
CN101374944B (zh) 2012-02-08
CA2633601A1 (en) 2007-06-21
IL192095A0 (en) 2008-12-29
EP1974020B1 (en) 2011-06-15
PT1974020E (pt) 2011-08-26
AU2006325236B2 (en) 2011-11-10
ES2367322T3 (es) 2011-11-02
CN101374944A (zh) 2009-02-25
KR20080097181A (ko) 2008-11-04
US20090270268A1 (en) 2009-10-29
EA200870062A1 (ru) 2009-04-28
US8338172B2 (en) 2012-12-25
CA2633601C (en) 2015-06-30
ZA200806094B (en) 2009-06-24
WO2007068758A1 (en) 2007-06-21
ATE513034T1 (de) 2011-07-15
NZ569816A (en) 2011-10-28
BRPI0619908A2 (pt) 2011-10-25

Similar Documents

Publication Publication Date Title
ZA200904907B (en) Antibodies against human cytomegalovirus (hCMV)
US20210189343A1 (en) Soluble Antibody Complexes for T Cell or NK Cell Activation and Expansion
Pachnio et al. Cytomegalovirus infection leads to development of high frequencies of cytotoxic virus-specific CD4+ T cells targeted to vascular endothelium
Gundry et al. A cell surfaceome map for immunophenotyping and sorting pluripotent stem cells
AU2018254566A1 (en) Oncolytic virotherapy and immunotherapy
MX2010007729A (es) Vectores de expresion de mamifero mejorados y uso de los mismos.
MXPA06010673A (es) Reduccion del riesgo de anticuerpos humanos anti-humano a traves de manipulacion del gen v.
WO2016201124A3 (en) T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
TN2010000616A1 (en) Human cytomegalovirus neutralising antibodies and use thereof
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
WO2007001737A3 (en) Methods and compositions for detecting herpes simplex virus type 2
Dang et al. Soluble CD27 induces IgG production through activation of antigen‐primed B cells
Mangare et al. Robust identification of suitable T-cell subsets for personalized CMV-specific T-cell immunotherapy using CD45RA and CD62L microbeads
WO2011050985A8 (en) Clonal expansion of b cells
Ramaswami et al. The polyomavirus BK large T-antigen-derived peptide elicits an HLA-DR promiscuous and polyfunctional CD4+ T-cell response
Vasquez et al. Rapid proliferation and differentiation of a subset of circulating IgM memory B cells to a CpG/cytokine stimulus in vitro
MX2022013956A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion especificas de cd70.
WO2009045075A3 (en) A monoclonal antibody specific to human embryonic stem cell, a hybridoma secreting the same and a method for detecting or isolating non-differenced embryonic stem cell
ATE533788T1 (de) Antikörper gegen cd44vra und methoden zu ihrer verwendung
WO2016168741A8 (en) Detection of human cytomegalovirus
Barbeau et al. Generation of a human induced pluripotent stem cell line (iPSC) from peripheral blood mononuclear cells of a patient with a myasthenic syndrome due to mutation in COLQ
WO2018232278A3 (en) PHOSPHO-RAB ANTIBODIES, ASSAYS AND METHODS OF USE
Park et al. P140Proper setting of cut-off value for the lymphocyte crossmatch by flow cytometry in kidney transplantation
Shi et al. Improving regulatory T cell production through mechanosensing
Al Zayer et al. P080 Case report, BANFF III rejection with IGM-donor specific antibody (DSA)